![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1355181
ÀÚ°¡Ç÷´çÃøÁ¤±â ½ÃÀå - ¼¼°è »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø(2018-2028³â)Self-monitoring Blood Glucose Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Product, By Application, By End User, By Region, Competition |
¼¼°è ÀÚ°¡Ç÷´çÃøÁ¤±â ½ÃÀåÀº 2022³â 18.4¾ï ´Þ·¯·Î Æò°¡µÇ¸ç 2028³â±îÁö ¿¬Æò±Õ 8.2%·Î ¿¹Ãø ±â°£ µ¿¾È °·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Ç÷´ç ¸ð´ÏÅ͸µÀº ´ç´¢º´ ȯÀÚ°¡ ½Ä»ç ¼·Ãë·®, Àν¶¸° ¿ë·® ¹× ¿îµ¿·®¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÏ»óÀûÀÎ °ü¸® °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÚ°¡ Ç÷´ç ÃøÁ¤(SMBG)Àº ȯÀÚ°¡ Ç÷´ç ÃøÁ¤±â¸¦ »ç¿ëÇÏ¿© Æ÷µµ´ç ¼öÄ¡¸¦ ½Å¼ÓÇÏ°Ô È®ÀÎÇÏ°í ¸ð¼¼ Ç÷°ü Æ÷µµ´ç ³óµµ¸¦ Á¤È®ÇÏ°Ô ÃøÁ¤ÇÏ´Â Çö´ë½Ä ´ç´¢º´ °ü¸® ÀýÂ÷ÀÔ´Ï´Ù. Å×½ºÆ® ½ºÆ®¸³, ¶õ¼Â ¹× Ç÷´ç ÃøÁ¤±â¸¦ Æ÷ÇÔÇÑ SMBG ±â¼úÀº Àå±âÀûÀÎ Ç÷´ç Á¶ÀýÀ» ÃËÁøÇÕ´Ï´Ù. ÃøÁ¤°ªÀ» ºÐ¼®ÇÔÀ¸·Î½á °³ÀÎÀº Ä¡·á¸¦ Á¶Á¤Çϰí, Ç×´ç´¢º´Á¦ ¹× ½ºÆ®·¹½º °ü¸®ÀÇ ¿µÇâÀ» Æò°¡Çϰí, ½Ä´Ü, Àν¶¸° ¿ë·®, ½Åü ¿îµ¿ µî¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ÀÌ Á¾ÇÕÀûÀÎ °úÁ¤¿¡´Â Áö¼ÓÀûÀÎ Ç÷´ç Á¶ÀýÀ» ´Þ¼ºÇϱâ À§ÇØ ½ÃÇèÁö, ¶õ¼Â ¹× Ç÷´ç ÃøÁ¤±â¸¦ »ç¿ëÇÏ´Â °ÍÀÌ Æ÷ÇԵ˴ϴÙ.
³ôÀº ´ç´¢º´ À¯º´·ü: ³ëÀÎ Àα¸ÀÇ Áõ°¡¿Í ³ôÀº ´ç´¢º´ À¯º´·ü, ´ç´¢º´°ú °ü·ÃµÈ À§Çè ¿äÀÎÀÇ Áõ°¡´Â Ç÷´ç ÀÚ°¡ ÃøÁ¤(SMBG) ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ, ±¹¹Î ÀÎ½Ä °³¼±À» À§ÇÑ Á¤ºÎÀÇ ³ë·Âµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ ±â±â´Â Ç÷¾× ³» Æ÷µµ´ç ³óµµ¸¦ Á¤È®ÇÏ°Ô ÃøÁ¤ÇÏ´Â °ÍÀÌ ¾Æ´Ï±â ¶§¹®¿¡ °á°ú°¡ ºÎÁ¤È®ÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡ À¯ÀÇÇØ¾ß ÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ±â±â¿¡ ´ëÇÑ »óȯ ºÎÁ·°ú ¾ö°ÝÇÑ ±ÔÁ¦´Â Àüü ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå °³¿ä | |
---|---|
¿¹Ãø ±â°£ | 2018-2028 |
2022³â ½ÃÀå ±Ô¸ð | 97¾ï 3,000¸¸ ´Þ·¯ |
2028³â ½ÃÀå ±Ô¸ð | 156¾ï 6,000¸¸ ´Þ·¯ |
CAGR 2023-2028 | 8% |
±Þ¼ºÀå ºÎ¹® | 2Çü ´ç´¢º´ |
ÃÖ´ë ½ÃÀå | ºÏ¹Ì |
ÀÌ·¯ÇÑ µµÀü¿¡µµ ºÒ±¸Çϰí, ½ÅÈï ½ÃÀå¿¡´Â ¹Ì°³¹ßµÈ ºñÁö´Ï½º ±âȸ°¡ ÀÖÀ¸¸ç, ´ç´¢º´ ¸ð´ÏÅ͸µ ±â±â¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È »õ·Î¿î Àü¸ÁÀÌ Ã¢ÃâµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ȯÀÚ ÀÎ½Ä ºÎÁ·, °í±Þ ±â±â ¹× ¾×¼¼¼¸®ÀÇ ³ôÀº ºñ¿ë µîÀÌ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±â¼úÀÇ ¹ßÀüÀº Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ Á¤È®¼º, »ç¿ë ÆíÀǼº ¹× ÀÇ·á ¼ºñ½º Á¦°øÀÚ¿ÍÀÇ ¿¬°á¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Áö¼ÓÀû Ç÷´ç ¸ð´ÏÅ͸µ(CGM) ½Ã½ºÅÛÀº ½Ç½Ã°£ Ç÷´ç ÃøÁ¤°ª°ú Ãß¼¼¸¦ Á¦°øÇÏ¿© ÀæÀº ÇΰŽºÆ½ °Ë»çÀÇ Çʿ伺À» ÃÖ¼ÒÈÇÕ´Ï´Ù. ¸ð¹ÙÀÏ ¾Û°ú ¹«¼± ¿¬°áÀÇ ÅëÇÕÀº µ¥ÀÌÅÍ °ü¸®¸¦ °ÈÇϰí ȯÀÚ °á°ú¸¦ Çâ»ó½ÃÄ×À¸¸ç, Abbott Laboratories, Medtronic plc, Roche Diabetes Care, Dexcom, Inc. Holdings AG¿Í °°Àº ½ÅÈï ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº Çõ½ÅÀûÀÎ Á¦Ç°À» Ãâ½ÃÇϱâ À§ÇØ R&D¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ȯÀÚÀÇ ¾ÈÀü°ú ±â±âÀÇ À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇØ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀº ¾ö°ÝÇÑ ±ÔÁ¦°¡ Àû¿ëµÇ°í ÀÖÀ¸¸ç, FDA¿Í EMA°¡ ±â±â ½ÂÀΰú ½ÃÆÇ ÈÄ Á¶»ç¸¦ °¨µ¶Çϰí ÀÖ½À´Ï´Ù. Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ºÐ¾ßÀÇ ±â¼ú ¹ßÀüÀÌ °¡¼ÓÈµÇ¸é¼ ¼¼°è ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ÀÌ·¯ÇÑ ÀåÄ¡´Â ÇöÀç ´Ù¾çÇÑ ÇüÅÂ, Å©±â ¹× °Ë»ç ±â°£À¸·Î ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÛ°í ÈÞ´ë °¡´ÉÇÑ ÀåÄ¡ÀÇ °³¹ßÀº Æí¸®ÇÑ Ãë±ÞÀ» ¿ëÀÌÇϰÔÇÏ¿© ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·áÀÇ ¹ßÀüÀº °íÇ÷´ç ¹× ÀúÇ÷´ç ´ç´¢º´ÀÇ Á¶±â ¹ß°ß¿¡ ±â¿©ÇÏ¿© ¼¼°è ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
»ýȰ½À°üÀÇ º¯È¿Í À½ÁÖ ¹× Èí¿¬ÀÇ Áõ°¡·Î ÀÎÇØ ´ç´¢º´ ȯÀÚ°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ·Î ÀÎÇØ ÀÌ·¯ÇÑ ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ºñ¸¸À²ÀÇ Áõ°¡´Â ÀÚ°¡Ç÷´çÃøÁ¤±â ¼¼°è ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ Àü ¼¼°è ³ëÀÎ Àα¸ÀÇ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ´ç´¢º´ ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °³ÀÎÀÇ ÀνÄÀÌ ³ô¾ÆÁö´Â °ÍÀº ¼¼°è ½ÃÀå È®´ëÀÇ ÁÖ¿ä ÃËÁøÁ¦ÀÔ´Ï´Ù. ±×·¯³ª Äڷγª ¹ÙÀÌ·¯½º ¹ß»ýÀº »ç¶÷µéÀÇ ¶óÀÌÇÁ½ºÅ¸ÀÏ¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ¹®´Ü¼ÓÀ¸·Î ÀÎÇØ Ȱµ¿ÀûÀÎ ÇൿÀÌ ¾É¾ÆÀÖ´Â ÇൿÀ¸·Î ¹Ù²î°í ÀÖ½À´Ï´Ù. °á°úÀûÀ¸·Î ÀÌ·¯ÇÑ ¿äÀεéÀº ´ç´¢º´ ȯÀÚÀÇ Áõ°¡·Î À̾îÁ® ÀÌ·¯ÇÑ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ´ç´¢º´ ȯÀÚ¸¦ ÁÙÀ̱â À§ÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºêÀÇ ±ÞÁõÀº ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ÀÚ°¡Ç÷´çÃøÁ¤±â ½ÃÀåÀÇ ±Ëµµ¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.
°í·ÉÈ »çȸ´Â ´ç´¢º´¿¡ °É¸®±â ½±½À´Ï´Ù. ÀÚ°¡Ç÷´çÃøÁ¤±â´Â ³ëÀÎÀÇ ¿ä±¸¸¦ ÃæÁ·½ÃŰ°í ±×µéÀÌ µ¶¸³ÀûÀ¸·Î È¿À²ÀûÀ¸·Î ´ç´¢º´À» °ü¸® ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ³ªÀ̰¡ µé¸é ¼¼Æ÷´Â Àν¶¸°¿¡ ´ëÇÑ °¨¼ö¼ºÀÌ °¨¼ÒÇÏ¿© Àν¶¸° ÀúÇ×¼ºÀ¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °¨¼ö¼º °¨¼Ò´Â ½Åü°¡ Ç÷´çÀ» È¿°úÀûÀ¸·Î Á¶ÀýÇÏ´Â °ÍÀ» ¾î·Æ°Ô ¸¸µì´Ï´Ù. ¸¹Àº ³ëÀεéÀÌ ¾É¾Æ¼ »ýȰÇÏ´Â °æ¿ì°¡ ¸¹¾Æ üÁß Áõ°¡¿Í Àν¶¸° ÀúÇ×¼ºÀ» ¾ÇȽÃŰ´Â ¿øÀÎÀÌ µË´Ï´Ù. ¼ö³â°£ÀÇ °Ç°¿¡ ÇØ·Î¿î ½Ä½À°üÀº ºñ¸¸°ú ´ë»ç Àå¾Ö¸¦ ÀÏÀ¸ÄÑ Á¦2Çü ´ç´¢º´ÀÇ À§ÇèÀ» Áõ°¡½Ã۴µ¥, ¿¤ÇÁ ¸ð´ÏÅ͸µ Ç÷´ç ÃøÁ¤ ÀåÄ¡´Â ³ëÀεéÀÌ ÁýÀ̳ª À̵¿ Áß¿¡µµ Ç÷´ç ¼öÄ¡¸¦ È®ÀÎÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. Á¤±âÀûÀÎ ¸ð´ÏÅ͸µÀ» ÅëÇØ ÀÚ½ÅÀÇ »óŸ¦ ÆÄ¾ÇÇϰí Ä¡·á °èȹ¿¡ ÇÊ¿äÇÑ Á¶Á¤À» ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÚ°¡ Ç÷´ç ÃøÁ¤±â¸¦ »ç¿ëÇÏ¸é ³ëÀÎÀÌ µ¶¸³ÀûÀ¸·Î ´ç´¢º´À» °ü¸®ÇÒ ¼ö ÀÖÀ¸¸ç, ÀÏ»óÀûÀÎ ¸ð´ÏÅ͸µ¿¡¼ ´Ù¸¥ »ç¶÷¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.
È¿°úÀûÀÎ ´ç´¢º´ °ü¸®¸¦ À§Çؼ´Â Á¤±âÀûÀ̰í ÀϰüµÈ Ç÷´ç ¸ð´ÏÅ͸µÀÌ ÇʼöÀûÀÔ´Ï´Ù. ÇÏÁö¸¸ ÀϺΠ»ç¶÷µéÀº °Ç¸ÁÁõ, °Ë»ç¿¡ ´ëÇÑ ºÒÆíÇÔ, ¶Ç´Â µ¿±âºÎ¿©ÀÇ ÀúÇÏ·Î ÀÎÇØ ¼øÀÀµµ°¡ ¶³¾îÁö´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù. ÀÚ°¡ Ç÷´ç ÃøÁ¤±â¸¦ Á¦´ë·Î »ç¿ëÇÏ·Á¸é ¾î´À Á¤µµÀÇ ±â¼ú·Â°ú Áö½ÄÀÌ ÇÊ¿äÇÕ´Ï´Ù. °í·ÉÀÚ³ª ¼ÕÀÌ ºÒÆíÇÑ »ç¶÷ Áß ÀϺδ ±â±â¸¦ ¿Ã¹Ù¸£°Ô Á¶ÀÛÇÏ´Â µ¥ ¾î·Á¿òÀ» °ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÚ°¡ Ç÷´ç ÃøÁ¤±â´Â ½Å·ÚÇÒ ¼ö ÀÖ´Â °á°ú¸¦ ¾ò±â À§ÇØ Á¤È®ÇÏ°Ô º¸Á¤Çϰí À¯Áö °ü¸®ÇØ¾ß ÇÕ´Ï´Ù. À߸øµÈ ±³Á¤À̳ª ¸¸·á µÈ Å×½ºÆ® ½ºÆ®¸³À» »ç¿ëÇÏ¸é ºÎÁ¤È® ÇÑ ÃøÁ¤ °ªÀ¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù.
´ç´¢º´ Áø´ÜÀ» ¹ÞÁö ¾ÊÀº »ç¶÷ÀÌ »ó´ç¼ö Á¸ÀçÇÑ´Ù´Â °ÍÀº ƯÈ÷ ½ÅÈï±¹¿¡¼ Ç÷´ç ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ º¸±Þ·üÀ» ³·Ãß´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. Áß±¹, Àεµ, ³²¾ÆÇÁ¸®Ä«°øÈ±¹, ºê¶óÁú µîÀÇ ±¹°¡¿¡¼´Â ¼±Áø±¹¿¡ ºñÇØ Áø´Ü Áö¿¬ÀÇ À¯º´·üÀÌ ³ô½À´Ï´Ù. ¶ÇÇÑ ´ç´¢º´°ú °°Àº ¸¸¼º Áúȯ¿¡ ´ëÇÑ ÀϹÝÀÎÀÇ ³·Àº ÀνÄ, ¼±Áø ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ Á¦ÇÑµÈ Á¢±Ù¼º, Á¤ºÎ ¹× ¹Î°£ ±â°üÀÇ ÀüÅëÀûÀÎ Ä¡·á¹ýÀÌ ºÎÁ·ÇÑ °Íµµ ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î, ±¹Á¦´ç´¢º´¿¬ÇÕÀÌ 2021³â¿¡ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é, ¾ÆÇÁ¸®Ä«¿¡¼´Â ´ç´¢º´ ȯÀÚÀÇ Àý¹Ý °¡±îÀ̰¡ ¹ÌÁø´Ü »óÅ·Π³²¾Æ ÀÖÀ¸¸ç, ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼´Â ¹ÌÁø´Ü ´ç´¢º´ ȯÀÚÀÇ ºñÀ²ÀÌ ¾à 55.0%¿¡ ´ÞÇϸç ÁÖ·Î Àεµ, Áß±¹, Àεµ³×½Ã¾Æ µî ±¹°¡°¡ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº CGM ¹× SMBG ½Ã½ºÅÛ¿¡ ´ëÇÑ »óȯ °èȹÀÇ ºÎÀç¿Í ÇÔ²² Áø´Ü ¹× Ä¡·áÀ² ÀúÇÏ¿¡ Å©°Ô ±â¿©Çϰí ÀÖÀ¸¸ç, ÀÌ·Î ÀÎÇØ °³¹ßµµ»ó±¹¿¡¼ÀÇ ½Ã½ºÅÛ µµÀÔÀÌ Á¦Çѵǰí ÀÖ½À´Ï´Ù.
ÀÚ°¡ Ç÷´ç ÃøÁ¤(SMBG) ±â±â ½ÃÀå¿¡¼ »ç¾÷À» Àü°³ÇÏ´Â ÁÖ¿ä ±â¾÷µéÀº ½ÃÀå¿¡¼ÀÇ ÀÔÁö¸¦ °ÈÇϱâ À§ÇØ Çõ½ÅÀûÀÎ ±â¼ú ¼Ö·ç¼Ç °³¹ß¿¡ Àü·«ÀûÀ¸·Î ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 8¿ù, »ó¾÷È ´Ü°èÀÇ ÀÇ·á ±â¼ú ¹× µðÁöÅÐ °Ç° ±â¾÷ÀÎ Intuity Medical, Inc.´Â ´ç´¢º´ ȯÀÚÀÇ »îÀ» ´Ü¼øÈÇϱâ À§ÇØ POGO Automatic(R) Blood Glucose Monitoring SystemÀ» The Intuity MedicalÀÇ POGO AutomaticÀº 10°³ÀÇ Å×½ºÆ® īƮ¸®Áö ±â¼úÀ» Ư¡À¸·Î ÇÏ´Â À¯ÀÏÇÑ FDA ½ÂÀÎ ÀÚµ¿ Ç÷´ç ÃøÁ¤±â·Î, ´ç´¢º´ ȯÀÚ°¡ ·£½Ë°ú Å×½ºÆ® ½ºÆ®¸³À» ºÐ¸®ÇÏ¿© »ç¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â À¯ÀÏÇÑ FDA ½ÂÀÎ ÀÚµ¿ Ç÷´ç ÃøÁ¤±â´Ù. ´ç´¢º´ ȯÀÚ°¡ ·£½Ë°ú Å×½ºÆ® ½ºÆ®¸³À» µû·Î µé°í ´Ù´Ï°Å³ª ·ÎµåÇÒ Çʿ䰡 ¾ø½À´Ï´Ù. ¹öư Çϳª¸¸ ´©¸£¸é ½±°Ô õÀÚ, äÇ÷ ¹× Æ÷µµ´ç ÃøÁ¤À» ÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÀÚ±Ý Á¶´Þ°ú ÅõÀÚ Áõ°¡´Â R&D Ȱµ¿°ú »õ·Î¿î ±â¼ú ¹ßÀü ¹× ÇÁ·ÎÁ§Æ®¸¦ ÃËÁøÇÕ´Ï´Ù. ½ÃÀå °ü°èÀÚµéÀº È¿À²¼º Çâ»óÀ» À§ÇÑ µðÁöÅÐ Çõ½ÅÀ» À§ÇØ Àڱݰú ÅõÀÚ¸¦ È®º¸Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 9¿ù, ¸¸¼º ÁúȯÀÇ ¿¹¹æ, Áø´Ü ¹× °ü¸® °È¿¡ Æ¯ÈµÈ ¿µ±¹ÀÇ ±â¼ú Ç÷§ÆûÀÎ Transdermal Diagnostics´Â 110¸¸ ÆÄ¿îµå(¹ÌÈ 131¸¸ ´Þ·¯)ÀÇ »çÀü ½Ãµå ÅõÀÚ ¶ó¿îµå¸¦ ¼º°øÀûÀ¸·Î ¿Ï·áÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ÀÚ±ÝÀº ºñ¿ë È¿À²ÀûÀ̰í 100% ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê´Â Ç÷´ç ¸ð´ÏÅ͸¦ °³¹ßÇÏ¿© Àú·ÅÇÑ Ç÷´ç ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±ÇÏ°í ´ç´¢º´ ȯÀÚ°¡ ´õ ¿À·¡ °Ç°ÇÏ°Ô »ì ¼ö ÀÖµµ·Ï µ½´Â µ¥ Ȱ¿ëµÉ ¿¹Á¤ÀÔ´Ï´Ù. ´ç´¢º´ ȯÀÚµéÀº °íÅë ¾øÀÌ Ç÷´ç ¼öÄ¡¸¦ ¸ð´ÏÅ͸µÇÏ¿© Áõ»ó ÁøÇàÀ» ´ÊÃ߰ųª ¸ØÃâ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ 2022³â 5¿ù¿¡´Â ¼¼°è »ý¸í°úÇÐ ±â¾÷ÀÌÀÚ »ó¾÷¿ë °Ë»ç±â°üÀÎ ·¦ÄÚÇÁ(Labcorp)°¡ ¼Ò·®ÀÇ Ç÷¾× »ùÇ÷ΠÇì¸ð±Û·Îºó A1c¸¦ ÃøÁ¤ÇØ ´ç´¢º´ À§ÇèÀ» Æò°¡ÇÒ ¼ö ÀÖ´Â °¡Á¤¿ë äÃë ŰƮ¸¦ Ãâ½ÃÇϱ⵵ Çß½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È º´¿ø ºÎ¹®ÀÌ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â º´¿øÀÇ ÀÎÇÁ¶ó ±¸Ãà°ú ÀÇ·áºñ ÁöÃâ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, BGM ÀåÄ¡´Â ¸î ÃÊ ³»¿¡ ½Å·ÚÇÒ ¼ö ÀÖ´Â µ¥ÀÌÅ͸¦ Àǻ翡°Ô Á¦°øÇÏ¿© ¿Ü·¡ ¹× ÀÔ¿ø ȯÀÚ È¯°æ¿¡¼ ȯÀÚ Ä¡·áÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ º´¿ø¿¡´Â ȯÀÚ Á¤º¸ ÀúÀå ¹× Àü¼Û¿¡ ´ëÇÑ °·ÂÇÑ ±ÔÁ¤ÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, COVID-19 ÆÒµ¥¹Í¿¡ ´ëÀÀÇÏ¿© FDA´Â º´¿ø¿¡¼ CGM ±â±â »ç¿ëÀ» Çã¿ëÇϰí ÀÖÀ¸¸ç, ÇâÈÄ ÆÒµ¥¹Í °¡´É¼ºÀº ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿ëµµ Ãø¸é¿¡¼ ½ÃÀåÀº Àӽżº ´ç´¢º´, Á¦ 2 Çü ´ç´¢º´, Á¦ 1 Çü ´ç´¢º´À¸·Î ºÐ·ùµÇ¸ç, Á¦ 2 Çü ´ç´¢º´Àº Àü ¼¼°è ÀÚ°¡ Ç÷´ç ÃøÁ¤±â ½ÃÀå¿¡¼ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. À̰ÍÀº ´ç ¼öÄ¡ ó¸® ¹× ¸ð´ÏÅ͸µ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¸¸¼º Æò»ý »óÅÂÀ̸ç, Á¦ 2 Çü ´ç´¢º´Àº °¡Àå ÈçÇÑ ´ç´¢º´À¸·Î Àü ¼¼°è ´ç´¢º´ ȯÀÚÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù. ƯÈ÷ ÁÂ½Ä »ýȰ ½À°ü, °Ç°¿¡ ÇØ·Î¿î ½Ä½À°ü, ºñ¸¸°ú °°Àº »ýȰ ½À°ü ¿äÀÎÀ¸·Î ÀÎÇØ Á¦ 2 Çü ´ç´¢º´ÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÚ°¡ Ç÷´ç ÃøÁ¤±â ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, Á¦ 2 Çü ´ç´¢º´ÀÇ È¿°úÀûÀÎ °ü¸®¸¦ À§Çؼ´Â Á¤±âÀû ÀÎ Ç÷´ç ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÚ°¡ Ç÷´ç ÃøÁ¤±â´Â Á¦2Çü ´ç´¢º´ ȯÀÚ°¡ Ç÷´ç ¼öÄ¡¸¦ ÃßÀûÇϰí Ä¡·á °èȹ¿¡ ÇÊ¿äÇÑ Á¶Á¤À» ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ¸ç ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
¹Ì±¹¿¡¼´Â ´ç´¢º´ ȯÀÚ ¹ß»ý·ü°ú À¯º´·üÀÌ Áõ°¡Çϰí ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÚ°¡Ç÷´çÃøÁ¤(SMBG) ±â±âÀÇ »ç¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â SMBG ±â±âÀÇ º¸±Þ, ³ôÀº ¼ÒºñÀÚ ÀÎÁöµµ, À¯¸®ÇÑ »óȯ Á¤Ã¥ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ Áö¹èÀûÀÎ ½ÃÀåÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áö³ 20³â°£ ºÏ¹Ì Áö¿ªÀÇ ´ç´¢º´ À¯º´·üÀº Å©°Ô Áõ°¡ÇßÀ¸¸ç, ±× ÁÖ¿ä ¿øÀÎÀº ºñ¸¸ÀÇ Áõ°¡¿Í »ýȰ½À°üÀÇ º¯È·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ª¿¡¼´Â ź¼öȹ° ¼Òºñ°¡ ¸¹¾Æ ºñ¸¸À² Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì Áö¿ª Áß¿¡¼µµ ¹Ì±¹Àº ¸¸¼ºÁúȯÀÌ ºü¸£°Ô Áõ°¡ÇÏ´Â ±¹°¡ Áß ÇϳªÀ̸ç, SMBG ÀåºñÀÇ °¡Àå Å« ¼ö¿ä âÃâ ±¹°¡ Áß ÇϳªÀÔ´Ï´Ù.
Tech Sci ResearchÀÇ ½ÃÀå Á¶»ç º¸°í¼ÀÎ "ÀÚ°¡Ç÷´çÃøÁ¤±â ¼¼°è ½ÃÀå"Àº ÁÖ¾îÁø ½ÃÀå µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °íÀ¯ÇÑ ¿ä±¸¿¡ ¸Â°Ô »ç¿ëÀÚ Á¤ÀÇÇÒ ¼ö ÀÖ´Â ±â´ÉÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ º¸°í¼´Â ´ÙÀ½°ú °°Àº Ä¿½ºÅ͸¶ÀÌ¡ÀÌ °¡´ÉÇÕ´Ï´Ù.
The Global Self-monitoring Blood Glucose Devices Market was valued at USD 18.4 billion in 2022 and is projected to experience robust growth in the forecast period, with a CAGR of 8.2% through 2028. Blood glucose monitoring plays a crucial role in empowering diabetic patients to make well-informed daily management decisions regarding food intake, insulin dosage, and physical exercise. Self-monitoring blood glucose (SMBG) represents a contemporary diabetes management procedure that involves the use of blood glucose meters by patients to quickly check their glucose levels and obtain accurate measurements of capillary glucose concentration. SMBG technology, encompassing test strips, lancets, and blood glucose meters, facilitates long-term glycemic control. By analyzing readings, individuals can adjust treatment, evaluate the impact of antidiabetic medications and stress management, and make informed decisions regarding diet, insulin dosage, and physical exercise, among other factors. This comprehensive process involves the utilization of test strips, lancets, and blood glucose meters to achieve sustained glycemic control.
High Prevalence of Diabetes: The increase in the geriatric population and the high prevalence of diabetes, along with the rising risk factors associated with diabetes, are key drivers for the growth of the self-monitoring of blood glucose (SMBG) market. Furthermore, government initiatives aimed at raising awareness among the population also contribute to the market's growth. However, it should be noted that the devices do not measure the exact level of glucose in the blood, which can result in inaccurate results. Moreover, the lack of reimbursement and stringent regulations for these devices may hinder the overall market growth.
Market Overview | |
---|---|
Forecast Period | 2018-2028 |
Market Size 2022 | USD 9.73 Billion |
Market Size 2028 | USD 15.66 Billion |
CAGR 2023-2028 | 8% |
Fastest Growing Segment | Type 2 Diabetes |
Largest Market | North America |
Despite these challenges, there are untapped opportunities in emerging markets, and the growing awareness about diabetes monitoring devices is expected to generate new prospects within the forecast period. However, challenges such as the lack of patient awareness and the high cost of advanced devices and accessories are projected to impede the market's growth.
Technological advancements have revolutionized the blood glucose monitoring devices market, enhancing accuracy, user-friendliness, and connectivity with healthcare providers. Continuous Glucose Monitoring (CGM) systems, for instance, offer real-time glucose readings and trends, minimizing the need for frequent fingerstick tests. The integration of mobile apps and wireless connectivity has bolstered data management and improved patient outcomes. Leading market players such as Abbott Laboratories, Medtronic plc, Roche Diabetes Care, Dexcom, Inc., and Ascensia Diabetes Care Holdings AG are investing in research and development to introduce innovative products. Stringent regulations govern the blood glucose monitoring devices market to ensure patient safety and device efficacy, with device approval and post-market surveillance overseen by the FDA and EMA. The rise in technological advancements in the field of blood glucose monitoring devices is driving the growth of the global market. With advancing technology, these devices are now widely accessible in different forms, sizes, and testing durations. The development of compact and portable devices facilitates convenient handling, thereby increasing demand. Furthermore, medical advancements contribute to the early detection of hyper and hypoglycemic diabetes, thus further fueling global market growth.
The changing lifestyle and increasing prevalence of alcohol and smoking consumption have contributed to a continuous rise in diabetes cases, resulting in a heightened demand for such devices. The escalating rates of obesity further drive the growth of the global self-monitoring blood glucose devices market. Additionally, the expanding geriatric population worldwide is fueling market growth. The growing awareness among individuals regarding preventive care for diabetes is a key driver for the global market's expansion. However, the outbreak of the coronavirus has significantly impacted people's lifestyles, with lockdown measures transforming active behaviors into sedentary ones. Consequently, these factors have led to an increase in diabetes cases and subsequently boosted the demand for such devices. The surge in government initiatives aimed at reducing diabetes cases has positively influenced the trajectory of the global self-monitoring blood glucose devices market throughout the forecast period.
The aging population is more susceptible to developing diabetes. Self-monitoring blood glucose devices cater to the needs of elderly individuals, allowing them to manage their diabetes independently and efficiently. s people age, their cells may become less sensitive to insulin, leading to insulin resistance. This reduced sensitivity makes it more challenging for the body to regulate blood glucose levels effectively. Many older adults may lead more sedentary lifestyles, which can contribute to weight gain and worsen insulin resistance. Unhealthy eating habits over the years can lead to obesity and metabolic disorders, increasing the risk of type 2 diabetes. elf-monitoring blood glucose devices allow older adults to check their blood glucose levels at home or on the go. Regular monitoring helps them track their condition and make necessary adjustments to their treatment plan. With self-monitoring devices, elderly individuals can manage their diabetes independently, reducing their dependence on others for daily monitoring.
Regular and consistent blood glucose monitoring is essential for effective diabetes management. However, some individuals may struggle with adherence, either due to forgetfulness, discomfort associated with testing, or a lack of motivation. Properly using self-monitoring blood glucose devices requires some level of technical skill and knowledge. Some elderly individuals or those with limited dexterity may find it challenging to operate the devices correctly. Self-monitoring blood glucose devices need to be accurately calibrated and maintained to provide reliable results. Incorrect calibration or using expired test strips can lead to inaccurate readings.
The presence of a significant proportion of undiagnosed individuals with diabetes is a major contributing factor to the lower adoption of Blood Glucose Monitoring Systems, particularly in emerging countries. The prevalence of delayed diagnosis is higher in countries like China, India, South Africa, Brazil, and others, compared to developed nations. Additionally, limited awareness among the general population regarding chronic diseases such as diabetes mellitus, coupled with restricted access to advanced healthcare infrastructure and inadequate conventional procedures by government or private organizations, may impede growth.
For example, as per data published by the International Diabetes Federation in 2021, nearly half of the diabetes patients in Africa remain undiagnosed, while in the Asia Pacific region, the proportion of undiagnosed individuals with diabetes is around 55.0%, primarily driven by countries like India, China, and Indonesia. Thus, the aforementioned factors, alongside the absence of reimbursement plans for CGM & SMBG systems, significantly contribute to lower diagnosis and treatment rates, subsequently limiting the implementation of these systems in developing countries.
Prominent companies operating in the self-monitoring blood glucose (SMBG) devices market are strategically focused on developing innovative technological solutions to enhance their market position. For instance, in August 2022, Intuity Medical, Inc., a commercial-stage medical technology and digital health company committed to simplifying life with diabetes, introduced the POGO Automatic® Blood Glucose Monitoring System at over 2,200 US pharmacies operated by Kroger Health, the healthcare division of The Kroger Co. The POGO Automatic from Intuity Medical is the sole FDA-approved automatic blood glucose monitor featuring 10-test cartridge technology, eliminating the need for individuals with diabetes to carry or load separate lancets and test strips. It effortlessly lances, collects blood, and provides a glucose result with just a touch of a button.
Boosting funding and investments will facilitate research and development activities, as well as new technology advancements and projects. Market players are securing funding and investments aimed at digital transformation for improved efficiency. For example, in September 2022, Transdermal Diagnostics, a UK-based technology platform dedicated to enhancing the prevention, diagnosis, and management of chronic conditions, announced the successful completion of their oversubscribed £1.1 million ($1.31 million) pre-seed investment round. This funding will be utilized to develop a cost-effective, 100% needle-free glucose monitor, improving access to affordable blood sugar monitoring and assisting diabetics in leading longer, healthier lives. With the aid of Transdermal Diagnostics' new technology, individuals with diabetes may potentially slow down or even halt the progression of their condition by painlessly monitoring their blood glucose levels. Furthermore, in May 2022, Labcorp, a leading global life sciences company and commercial laboratory, launched an at-home collection kit that measures hemoglobin A1c and assesses the risk of diabetes using a small blood sample.
The hospitals segment is projected to dominate the market during the forecast period, driven by the improving infrastructure and increasing healthcare expenditure in hospitals. Furthermore, BGM devices provide reliable data to practitioners within seconds, enhancing patient care quality in both outpatient and inpatient settings. Hospitals also have robust provisions for storing and transferring patient information. Additionally, in response to the COVID-19 pandemic, the FDA authorized the use of CGM devices in hospitals, and the potential for future pandemics is expected to further drive segment growth.
The home care segment is anticipated to exhibit the highest growth rate throughout the forecast period. Self-monitoring of blood glucose has revolutionized home-based glucose monitoring and is widely adopted worldwide as a short-term glucose monitoring method. Self-monitoring blood glucose (SMBG) allows individuals, with or without diabetes, to measure their blood sugar levels in the comfort of their homes. This approach enables patients to assess the effects of their treatment, including diet, insulin, exercise, and stress management, based on their blood glucose readings.
In terms of application, the market can be categorized into gestational, type 2, and type 1 diabetes. Type 2 diabetes holds the largest market share in the global self-monitoring blood glucose devices market. It is a chronic, lifelong condition that affects the processing and monitoring of sugar levels. Type 2 diabetes is the most common form of diabetes, accounting for the majority of diabetes cases globally. The rising prevalence of Type 2 diabetes, particularly due to lifestyle factors like sedentary habits, unhealthy diets, and obesity, is contributing to the expanding market for self-monitoring blood glucose devices. Effective management of Type 2 diabetes requires regular blood glucose monitoring. Self-monitoring blood glucose devices play a vital role in helping individuals with Type 2 diabetes track their glucose levels and make necessary adjustments to their treatment plans, contributing to the market growth.
The escalating incidence and prevalence of diabetes patients, along with healthcare expenditure, in the United States indicate a growing utilization of Self-monitoring Blood Glucose (SMBG) devices. North America is projected to be the dominant market, driven by factors such as the widespread availability of SMBG devices, high consumer awareness, and favorable reimbursement policies. The prevalence of diabetes has witnessed a significant surge in the past two decades in North America, primarily attributed to the increased prevalence of obesity and lifestyle changes. Furthermore, the region exhibits higher carbohydrate consumption, which contributes to the rising obesity rates. The United States, within North America, represents one of the countries experiencing rapid growth in chronic diseases, and it stands as the largest demand-generating country for SMBG devices.
In this report, the Global Self-monitoring Blood Glucose Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Self-monitoring Blood Glucose Devices Market.
Global Self-monitoring Blood Glucose Devices Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report: